Tumor Mutational Burden: clinical utility in immunotherapy
Precision Medicine

Tumor Mutational Burden: clinical utility in immunotherapy

On June 16, 2020, the U.S. Food and Drug Administration granted accelerated tissue-agnostic approval to pembrolizumab for adult and pediatric patients with unresectable or metastatic solid tumors…

September 19, 2026 · 18 min read

Newest

About

Actionable intelligence for clinical pathology and diagnostics.